Trial Profile
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2018
Price :
$35
*
At a glance
- Drugs NC 4016 (Primary)
- Indications Liver cancer; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors NanoCarrier
- 22 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Jun 2017 New trial record